Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide and Cabergoline in NFPA and Resistant Prolactinomas
NCT01620138Phase 3Completed
- Sponsor
- Federal University of Rio de Janeiro
- Start
- Mar 2010
- Primary completion
- Jun 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pasireotide LAR in non-functioning pituitary adenoma (NFPA), prolactinoma, sponsored by Federal University of Rio de Janeiro. Started Mar 2010; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
non-functioning pituitary adenoma (NFPA)prolactinoma
Beyond the preview
Go deeper on NCT01620138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01620138.